Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Weifa
Evaluate
June 04, 2013
Asco – Clovis price is twice as nice following double cancer win
April 02, 2013
Clavis joins no-hope league as Elacyt strikes out
February 26, 2013
Event – Do or die for Clavis in leukaemia trial
January 09, 2013
Sarepta joins the big league as best-performing 2012 share
November 12, 2012
Leap failure sends Clavis and Clovis crashing back to earth
September 03, 2012
Event – Clovis hopes for a great leap forward with trial results
February 13, 2012
Therapeutic focus - Drugmakers brush off failure and keep trying in AML
January 18, 2012
Clavis making hay while sun shines on cancer candidate
December 02, 2011
Scandinavian biotech hit particularly hard in bad year for sector
December 03, 2009
EP Vantage Interview – Clovis up and running and seeking more deals
November 24, 2009
Clavis calls on experience of newcomer Clovis in cancer deal
Load More
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
May 15, 2023
Pharma’s Biggest Spenders 2022 Infographic
May 03, 2023
Gene Editing: Overhyped or Unstoppable Tide?
Editor's Picks
May 16, 2023
Heightened US antitrust fears rattle biopharma
May 11, 2023
2023’s biggest launches: the story so far
May 17, 2023
Viking’s Voyage is not over yet
May 09, 2023
Gene editing: overhyped or unstoppable tide?
May 16, 2023
A slow (and low) year for FDA approvals
